<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734354</url>
  </required_header>
  <id_info>
    <org_study_id>331-403-00024</org_study_id>
    <nct_id>NCT03734354</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese Subjects</brief_title>
  <official_title>A Single-center, Open-label Study Evaluating the Pharmacokinetics, Tolerability and Safety of Single Dose Oral Brexpiprazole Tablets in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, open-label study evaluating the pharmacokinetics, tolerability&#xD;
      and safety of single dose oral brexpiprazole tablets in healthy Chinese subjects. A total of&#xD;
      30 healthy adult subjects are to be enrolled into the study. Three dose groups will be set&#xD;
      up, with about 10 subjects in each dose group. Subjects will enter 1 mg, 2 mg and 4 mg dose&#xD;
      groups in sequence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 30 healthy adult subjects are to be enrolled into the study. Three dose groups&#xD;
      will be set up, with about 10 subjects in each dose group. Subjects will enter 1 mg, 2 mg and&#xD;
      4 mg dose groups in sequence.&#xD;
&#xD;
      After the clinical trial responsible physicians obtain the informed consent forms from&#xD;
      subjects, the subjects will be screened 14 days to 1 days prior to taking the study drug&#xD;
      (D-14~D-1).&#xD;
&#xD;
      One day prior to dosing in each group (D-1), the included subjects are hospitalized On the&#xD;
      next day (D1), after completed the hospitalization inspection, eligible subjects will be&#xD;
      assigned subject numbers to start with the first dose, complete corresponding examination,&#xD;
      stay in hospital for observation and be discharged on Day 4 of medication. On days 6, 8, 10,&#xD;
      12 blood samples are collected and safety evaluation will be performed. Telephone follow-up&#xD;
      will be performed on day Day31.&#xD;
&#xD;
      Blood samples are collected to determine and evaluate blood concentrations of Brexpiprazole&#xD;
      and its main metabolite DM-3411 before dosing, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72,&#xD;
      96, 120, 168, 216, 264 hours after dosing, with 18 sampling points in total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2019</start_date>
  <completion_date type="Actual">May 18, 2020</completion_date>
  <primary_completion_date type="Actual">May 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The peak concentration (Cmax) after the first administration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours</time_frame>
    <description>The peak concentration (Cmax) of Brexipiprazole and the metabolite DM-3411 after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The peak time (Tmax) after the first administration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours</time_frame>
    <description>The peak-time of Brexipiprazole and the metabolite DM-3411 on the first day after administration are calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC0-264h)</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours</time_frame>
    <description>The area under the plasma concentration-time curve of Brexipiprazole after administration are calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half time after the first administration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours</time_frame>
    <description>The half time of Brexipiprazole after administration are calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance after the first administration</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours</time_frame>
    <description>To assess the apparent clearance after administration (CL/F) of Brexipiprazole after the first administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of OPC-34712</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours</time_frame>
    <description>To assess the Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of OPC-34712</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>0, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours</time_frame>
    <description>To seeess blood pressure after administration of brexpiprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>0, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours</time_frame>
    <description>To seeess heart rate after administration of brexpiprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours</time_frame>
    <description>To seeess Body weight after administration of brexpiprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>3, 6, 24, 72, 96, 120, 264 hours</time_frame>
    <description>To seeess 12-lead ECG after administration of brexpiprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood biochemistry</measure>
    <time_frame>24, 96, 264 hours</time_frame>
    <description>To seeess blood biochemistry after administration of brexpiprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood routine</measure>
    <time_frame>24, 96, 264 hours</time_frame>
    <description>To seeess blood routine after administration of brexpiprazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary routine</measure>
    <time_frame>24, 96, 264 hours</time_frame>
    <description>To seeess urinary routine after administration of brexpiprazole</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Health</condition>
  <arm_group>
    <arm_group_label>1 mg dosing group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg dosing group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg dosing group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>Brexpiprazole , single/oral/with fasting</description>
    <arm_group_label>1 mg dosing group</arm_group_label>
    <arm_group_label>2 mg dosing group</arm_group_label>
    <arm_group_label>4 mg dosing group</arm_group_label>
    <other_name>Brex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Sign the informed consent form&#xD;
&#xD;
          -  2.At the age of 18~45 years old (including upper and lower limits) when signing the&#xD;
             informed consent form.&#xD;
&#xD;
          -  3.Body weight of not less than 50kg, BMI 19 ~ 24kg/m2 (including the upper and lower&#xD;
             limits) [ body mass index (BMI) = body weight (kg) / height2 (m2)].&#xD;
&#xD;
          -  4.Subjects determined by the investigator to be healthy according to the medical&#xD;
             history and the results of serological examination (HIV antibodies, HBsAg, HCV&#xD;
             antibodies and syphilis antibodies), physical examination, vital signs (body&#xD;
             temperature, blood pressure, heart rate), 12 lead ECG, laboratory tests (routine blood&#xD;
             tests, blood biochemical tests, routine urine tests).&#xD;
&#xD;
          -  5.Subjects agree to take appropriate contraceptive measures during the trial and&#xD;
             within 4 weeks after the dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Participated in any interventional clinical trial within 12 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  2.Drug abuse in the past 2 years or a history of abuse&#xD;
&#xD;
          -  3.Drinking alcohol more than 2 unit per day (1 unit= 360 ml beer , or 45 ml 4.0%&#xD;
             alcohol, or 150 ml liquor, or 50 ml wine ) 6 months before the screening, or subjects&#xD;
             can not stop drinking during the hospitalization&#xD;
&#xD;
          -  4.Smoking urine test or drug abuse urine test at screening is positive.&#xD;
&#xD;
          -  5.Taking grapefruit, seville orange, coffee, alcohol or food containing these&#xD;
             ingredients one week before taking the study drug.&#xD;
&#xD;
          -  6.Taking any other prescriptions or over-the-counter medications or Chinese herbal&#xD;
             medicine or vitamin 14 days prior to taking the test medication&#xD;
&#xD;
          -  7.Use of any drug that inhibits or induces CYP2D6 and CYP3A4 metabolic enzymes 30 days&#xD;
             prior to taking the study drug&#xD;
&#xD;
          -  8.At the discretion of the investigators, subjects' diet significantly deviates from&#xD;
             normal intake of protein, carbohydrate and fat (e.g. vegetarians or absolute&#xD;
             vegetarians).&#xD;
&#xD;
          -  9.Blood donation or equal blood loss (&gt; 350 ml) within 12 weeks prior to medication.&#xD;
&#xD;
          -  10.Past or present allergy to any medication.&#xD;
&#xD;
          -  11.HbA1c ≥ 6.0% at screening.&#xD;
&#xD;
          -  12.Urinary pregnancy test (HCG) is positive at screening or female subjects who were&#xD;
             in lactation.&#xD;
&#xD;
          -  13.Breath alcohol test positive.&#xD;
&#xD;
          -  14.Any positive result in HIV antibody, HBsAg, HCV antibody and syphilis serology&#xD;
             test.&#xD;
&#xD;
          -  15.Heart rate &lt;50 bpm or &gt;100 bpm at resting state.&#xD;
&#xD;
          -  16.Blood pressure at resting satate in prone positon, sitting position or standing&#xD;
             position &gt; 140/90 mmHg, or &lt; 90/60 mmHg.&#xD;
&#xD;
          -  17.Symptomatic hypotension or orthostatic hypotension (orthostatic hypotension is&#xD;
             defined as standing blood pressure, systolic blood pressure (SBP) dropped ≥30 mmHg&#xD;
             and/or diastolic blood pressure (DBP) decreased ≥20 mmHg after 3 minutes of resting&#xD;
             pressure in the supine position or present symptoms).&#xD;
&#xD;
          -  18.Previous or current organic illness (including but not limited to cardiovascular,&#xD;
             liver, kidney, nerve, digestive tract, respiratory tract, hematology, endocrine and&#xD;
             immune diseases ).Other conditions determined by the investigator could bring risk to&#xD;
             the subjects or interfere the result of the trial, including but not limited to drug&#xD;
             absorption, distribution, metabolism or excretion.&#xD;
&#xD;
          -  19.Previous or current psychological abnormality, mental or neurological disorders or&#xD;
             autonomic neuropathies that are considered potential by investigators to compromise or&#xD;
             influence the subject's ability to participate in the trial.&#xD;
&#xD;
          -  20.Subjects with abnormal digestion and absorption function (e.g. alimentary canal&#xD;
             excision history ).&#xD;
&#xD;
          -  21.Other subjects determined by the investigators not fit for the enrollment of the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Jiang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anding Hospital of Capital Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anding Hospital of Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 2, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

